About Bioline  All Journals  Testimonials  Membership  News

African Health Sciences
Makerere University Medical School
ISSN: 1680-6905
EISSN: 1680-6905
Vol. 20, No. 2, 2020, pp. 871-884
Bioline Code: hs20057
Full paper language: English
Document type: Study
Document available free of charge

African Health Sciences, Vol. 20, No. 2, 2020, pp. 871-884

 en Efficacy and safety of rituximab for systemic lupus erythematosus treatment: a meta-analysis
Wu, Shanshan; Wang, Yanhai; Zhang, Jiaojiao; Han, Bo; Wang, Baishan; Gao, Wanli; Zhang, Ning; Zhang, Cheng; Yan, Feng & Li, Zhijing


Background: Given the inconsistency of previous studies and the newly emerging evidence, we decided to conduct a meta-analysis.
Methods: The meta-analysis included 2 randomized controlled trials and 13 observational studies 742 patients in total. Qualified studies were properly searched from databases . Data were analyzed by the RevMan 5.3 software. Results were demonstrated as WMD , SMD and RR with 95% CIs, I2 and P value.
Results: we observed that a remarkable increase of complement C3 in the rituximab group than placebo group (WMDfixed=7.67mg/dL, 95%CIs=-0.16~15.50, I2=0%, P=0.05). A significant increase of complement C4 was observed in the rituximab group than placebo group (WMDfixed=3.14mg/dL, 95%CIs=1.06~5.22, I2 =0%, P=0.003). Notably decreased peripheral CD19+B cells in rituximab group than placebo group (WMDfixed=-117.93n/μl, 95%CIs=-172.94~-62.91, I2 =0%, P<0.0001) in RCTs. Patients with severe or refractory SLE got more satisfactory efficacy results after receiving rituximab in observational studies, such as British Isles Lupus Assessment Group index score, SLE Disease Activity Index score, complement C3/C4, anti-dsDNA antibodies, peripheral CD19+B cells and so on. Safety profiles were no difference between rituximab and placebo groups.
Conclusion: although the efficacy of rituximab is highly controversial for SLE, our study shows that rituximab presents a satisfying efficacy and safety for SLE.

Efficacy; safety; rituximab; systemic lupus erythematosus; meta-analysis.

© Copyright 2020 - Wu S et al.

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2023, Site last up-dated on 01-Sep-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Google Cloud Platform, GCP, Brazil